At a glance
- Originator GlaxoSmithKline
- Class Peptides
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 21 Nov 2001 Preclinical development for Obesity in USA (unspecified route)